These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3085419)

  • 1. Interindividual variation in the absorption of glibenclamide in man.
    Ikegami H; Shima K; Tanaka A; Tahara Y; Hirota M; Kumahara Y
    Acta Endocrinol (Copenh); 1986 Apr; 111(4):528-32. PubMed ID: 3085419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay.
    Matsuda A; Kuzuya T; Sugita Y; Kawashima K
    Horm Metab Res; 1983 Sep; 15(9):425-8. PubMed ID: 6416980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
    Rosak C; Haupt E; Walter T; Werner J
    Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Haupt E; Putschky F; Zoltobrocki M; Schöffling K
    Dtsch Med Wochenschr; 1984 Feb; 109(6):210-3. PubMed ID: 6421561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of action of combined administration of glibenclamide and insulin in type II diabetics with secondary failure of oral treatment].
    Schmidt FH; Klujko J; Kühnle HF; Reiter J
    Klin Wochenschr; 1986 Oct; 64(20):1021-3. PubMed ID: 3097384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.
    Sartor G; Melander A; Scherstén B; Wåhlin-Boll E
    Diabetologia; 1980 Jan; 18(1):17-22. PubMed ID: 6767639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapancreatic insulin effect of glibenclamide.
    Mulder H; Schopman W; van der Lely AJ
    Eur J Clin Pharmacol; 1991; 40(4):379-81. PubMed ID: 1904820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical application of the hypoglycemic agent glibenclamide and changes in blood glucose, plasma insulin (IRI) levels and plasma concentration of glibenclamide in normal rats.
    Yamamoto T; Katakabe K; Akiyoshi K; Kan K; Asano T; Okumura M
    Diabetes Res Clin Pract; 1990 Jan; 8(1):19-22. PubMed ID: 2105197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus.
    Hoffman A; Fischer Y; Gilhar D; Raz I
    Eur J Clin Pharmacol; 1994; 47(1):53-5. PubMed ID: 7988624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation by previous nutrients of glibenclamide-induced insulin release in man. An effect which is counteracted by meal-induced retardation of drug absorption.
    Grill V; Efendić S; Regitz G
    Scand J Clin Lab Invest; 1986 Oct; 46(6):527-32. PubMed ID: 3095909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes.
    Arnqvist HJ; Karlberg BE; Melander A
    Ann Clin Res; 1983; 15 Suppl 37():21-5. PubMed ID: 6433769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a gel forming dietary fiber, guar gum, on the absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes.
    Uusitupa M; Södervik H; Silvasti M; Karttunen P
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):153-7. PubMed ID: 2110937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man.
    Shima K; Tanaka A; Ikegami H; Tabata M; Sawazaki N; Kumahara Y
    Horm Metab Res; 1983 Jan; 15(1):1-3. PubMed ID: 6299917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved effect of glibenclamide on administration before breakfast.
    Sartor G; Lundquist I; Melander A; Scherstén B; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 21(5):403-8. PubMed ID: 6804245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behaviour of glibenclamide on repeated administration to diabetic patients.
    Balant L; Zahnd GR; Weber F; Fabre J
    Eur J Clin Pharmacol; 1977; 11(1):19-25. PubMed ID: 401739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients.
    Kyllästinen M; Groop L
    Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of different regimens of drug administration on the absorption and plasma concentration of glibenclamide].
    Chen H; Pan CY; Li JY
    Zhonghua Nei Ke Za Zhi; 1988 Sep; 27(9):539-40, 586. PubMed ID: 3147856
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.